Showing 2591-2600 of 2652 results for "".
- Market Scope: Ophthalmic Laser Market Expected to Total $400 Million in 2018https://modernod.com/news/market-scope-ophthalmic-laser-market-expected-to-total-400-million-in-2018/2479885/Global revenues for ophthalmic lasers—photocoagulation, photodisruption (YAG), and SLT—along with maintenance, accessories, and endoprobes, will total more than $400 million in 2018 and grow
- SightMD, 24-Location Ophthalmology Group, and Chicago Pacific Founders Set Partnershiphttps://modernod.com/news/sightmd-24-location-ophthalmology-group-and-chicago-pacific-founders-set-partnership/2479899/SightMD, a provider of eyecare services through 24 locations, and Chicago Pacific Founders Fund LP, a health care investment fund, announced that they are entering into a partnership to expand SightMD’s patient-centric care model to patients, providers, and payers across the New York, New Jersey
- Innovative “Pay It Forward” Training Program for Specialty Eye Surgeonshttps://modernod.com/news/innovative-pay-it-forward-training-program-for-specialty-eye-surgeons/2479905/The Refractive Surgery Alliance (RSA) announced the creation of a new and innovative training program for vision correction surgeons. The RSA program structure is unique and recognizes the expanding and rapidly evolving field refractive surgery. Instead of training surgeons under a single
- Devices to Expand Role of Surgery in Glaucoma Treatmenthttps://modernod.com/news/devices-to-expand-role-of-surgery-in-glaucoma-treatment/2479914/The glaucoma surgical device market is expected to grow at a rate of nearly 23 percent over the next 5 years, according to a Market Scope report. The market is expected to grow to nearly $1.7 billion by 2023, up from a small base of just under $634 million in 2018. Minimally invasive glauc
- Roche’s Genentech Unit to Cut 223 Jobs in UShttps://modernod.com/news/roches-genentech-unit-to-cut-223-jobs-in-us/2479930/Roche’s Genentech unit plans to cut 223 jobs from its South San Francisco, California headquarters by the end of the year. The company, which disclosed the staff reductions in a Worker Adjustment and Retraining Notification (WARN) posted by the State of California’s Employment Develop
- FDA Approves 12-Week Dosing for Eylea in Wet AMD Patientshttps://modernod.com/news/fda-approves-12-week-dosing-for-eylea-in-wet-amd-patients/2479932/Regeneron announced that the FDA has approved a supplemental Biologics License Application for Eylea (aflibercept) injection in patients with wet age-related macular degeneration (AMD). The application was based on second-year data from the phase 3 VIEW 1 and 2 trials in which patients with wet A
- UnitedHealthcare Eye Care Program Aims to Give Children Access to Comprehensive Eye Exams and Glasseshttps://modernod.com/news/unitedhealthcare-eye-care-program-aims-to-give-children-access-to-comprehensive-eye-exams-and-glasses/2479940/UnitedHealthcare has launched a new program that aims to improve access to comprehensive eye exams and prescription glasses for children across the country, helping address the unique eye-health challenges young people face. The UnitedHealthcare Children’s Eye Care Program will help expand
- Breakthrough in AI Technology to Improve Care for Patientshttps://modernod.com/news/breakthrough-in-ai-technology-to-improve-care-for-patients/2479943/Two years ago, Moorfields Eye Hospital NHS Foundation Trust and DeepMind Health came together to announce a 5-year partnership to explore whether artificial intelligence (AI) technology could help clinicians improve care for patients. Researchers from Moorfields and the UCL Institute of Op
- Ocutech Introduces New Ves Falcon Autofocus Bioptic Telescopehttps://modernod.com/news/ocutech-introduces-new-ves-falcon-autofocus-bioptic-telescope/2479963/Following 6 years of development and testing, Ocutech has introduced its new VES Falcon Autofocus Bioptic Telescope, the company’s next generation autofocusing bioptic for the visually impaired. The Falcon is in initial limited release with select low-vision specialists in the United
- EyePoint Pharmaceuticals Appoints David Price as Chief Financial Officerhttps://modernod.com/news/eyepoint-pharmaceuticals-appoints-david-price-as-chief-financial-officer/2479969/EyePoint Pharmaceuticals announced the appointment of David Price as Chief Financial Officer, effective immediately. In this role, Mr. Price will oversee and lead the company’s financial and capital markets activities. Mr. Price brings to EyePoint more than 25 years of financial experience